Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of topical digoxin and furosemide gel for cutaneous warts
NL-OMON41194Phase 2Active, not recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Dec 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of digoxin and furosemide in verruca and human papillomavirus infection (4 arms), sponsored by Centre for Human Drug Research. Primary endpoints: Percent reduction in wart area at Week 6 compared with baseline, Percent reduction in wart area at Weeks 10 and 14 compared with baseline and 6 more. Started Dec 2014; status: active, not recruiting.
02
Drugs
digoxinfurosemide
03
Conditions
verrucahuman papillomavirus infection
Beyond the preview
Go deeper on NL-OMON41194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41194.